Background The deposition and oligomerization of amyloid β (Aβ) peptide plays a key role in the pathogenesis of Alzheimer's disease (AD). Aβ peptide arises from cleavage of the membrane-associated domain of the amyloid precursor protein (APP) by β and γ secretases. Several lines of evidence point to the soluble Aβ oligomer (AβO) as the primary neurotoxic species in the etiology of AD. Recently, we have demonstrated that a class of fluorene molecules specifically disrupts the AβO species. Methodology/Principal Findings To achieve a better understanding of the mechanism of action of this disruptive ability, we extend the application of electron paramagnetic resonance (EPR) spectroscopy of site-directed spin labels in the Aβ peptide to investigate the binding and influence of fluorene compounds on AβO structure and dynamics. In addition, we have synthesized a spin-labeled fluorene (SLF) containing a pyrroline nitroxide group that provides both increased cell protection against AβO toxicity and a route to directly observe the binding of the fluorene to the AβO assembly. We also evaluate the ability of fluorenes to target multiple pathological processes involved in the neurodegenerative cascade, such as their ability to block AβO toxicity, scavenge free radicals and diminish the formation of intracellular AβO species. Conclusions Fluorene modified with pyrroline nitroxide may be especially useful in counteracting Aβ peptide toxicity, because they posses both antioxidant properties and the ability to disrupt AβO species.
References
[1]
LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8: 499–509.
[2]
Klein WL, Stine WB Jr, Teplow DB (2004) Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25: 569–580.
[3]
Maezawa I, Hong HS, Liu R, Wu CY, Cheng RH, et al. (2008) Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem 104: 457–468.
[4]
Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352–357.
Hong HS, Maezawa I, Budamagunta M, Rana S, Shi A, et al. (2010) Candidate anti-Abeta fluorene compounds selected from analogs of amyloid imaging agents. Neurobiol Aging 31: 1690–1699.
[7]
Lee CW, Kung MP, Hou C, Kung HF (2003) Dimethylamino-fluorenes: ligands for detecting beta-amyloid plaques in the brain. Nucl Med Biol 30: 573–580.
[8]
Hong HS, Rana S, Barrigan L, Shi A, Zhang Y, et al. (2009) Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo. J Neurochem 108: 1097–1108.
[9]
Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787–795.
[10]
Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5: 160–170.
[11]
Farooqui AA, Yang HC, Horrocks L (1997) Involvement of phospholipase A2 in neurodegeneration. Neurochem Int 30: 517–522.
[12]
Hideg K, Kalai T (2007) Novel antioxidants in anthracycline cardiotoxicity. Cardiovasc Toxicol 7: 160–164.
[13]
Mandal R, Kutala VK, Khan M, Mohan IK, Varadharaj S, et al. (2007) N-hydroxy-pyrroline modification of verapamil exhibits antioxidant protection of the heart against ischemia/reperfusion-induced cardiac dysfunction without compromising its calcium antagonistic activity. J Pharmacol Exp Ther 323: 119–127.
[14]
Cai L, Innis RB, Pike VW (2007) Radioligand development for PET imaging of beta-amyloid (Abeta)–current status. Curr Med Chem 14: 19–52.
[15]
Kalai T, Petrlova J, Balog M, Aung HH, Voss JC, et al. (2011) Synthesis and study of 2-amino-7-bromofluorenes modified with nitroxides and their precursors as dual anti-amyloid and antioxidant active compounds. Eur J Med Chem 46: 1348–1355.
[16]
Hong HS, Maezawa I, Yao N, Xu B, Diaz-Avalos R, et al. (2007) Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Abeta oligomer-induced cytotoxicity. Brain Res 1130: 223–234.
[17]
Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486–489.
[18]
Petrlova J, Hong HS, Bricarello DA, Harishchandra G, Lorigan GA, et al. (2011) A differential association of Apolipoprotein E isoforms with the amyloid-beta oligomer in solution. Proteins 79: 402–416.
[19]
Barrow CJ, Yasuda A, Kenny PT, Zagorski MG (1992) Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J Mol Biol 225: 1075–1093.
[20]
Kelly SM, Jess TJ, Price NC (2005) How to study proteins by circular dichroism. Biochim Biophys Acta 1751: 119–139.
[21]
Liao MQ, Tzeng YJ, Chang LY, Huang HB, Lin TH, et al. (2007) The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Abeta peptides. FEBS Lett 581: 1161–1165.
[22]
Lam MA, Pattison DI, Bottle SE, Keddie DJ, Davies MJ (2008) Nitric oxide and nitroxides can act as efficient scavengers of protein-derived free radicals. Chem Res Toxicol 21: 2111–2119.
[23]
Twomey P, Taira J, DeGraff W, Mitchell JB, Russo A, et al. (1997) Direct evidence for in vivo nitroxide free radical production from a new antiarrhythmic drug by EPR spectroscopy. Free Radic Biol Med 22: 909–916.
[24]
Glebska J, Pulaski L, Gwozdzinski K, Skolimowski J (2001) Structure-activity relationship studies of protective function of nitroxides in Fenton system. Biometals 14: 159–170.
[25]
Li J, Liu R, Lam KS, Jin LW, Duan Y (2011) Alzheimer's disease drug candidates stabilize A-beta protein native structure by interacting with the hydrophobic core. Biophys J 100: 1076–1082.
[26]
Berliner LJ, Grunwald J, Hankovszky HO, Hideg K (1982) A novel reversible thiol-specific spin label: papain active site labeling and inhibition. Anal Biochem 119: 450–455.
[27]
Sopher BL, Fukuchi K, Smith AC, Leppig KA, Furlong CE, et al. (1994) Cytotoxicity mediated by conditional expression of a carboxyl-terminal derivative of the beta-amyloid precursor protein. Brain Res Mol Brain Res 26: 207–217.
[28]
Likhtenshtein GI (1993) Biophysical labeling methods in molecular biology. New York: Cambridge University Press. pp. 46–79.
[29]
Jin LW, Shie FS, Maezawa I, Vincent I, Bird T (2004) Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol 164: 975–985.
[30]
Maezawa I, Jin LW, Woltjer RL, Maeda N, Martin GM, et al. (2004) Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. J Neurochem 91: 1312–1321.
[31]
Maezawa I, Hong HS, Wu HC, Battina SK, Rana S, et al. (2006) A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid-beta oligomeric complexes. J Neurochem 98: 57–67.
[32]
Wu J, Breydo L, Isas JM, Lee J, Kuznetsov YG, et al. (2009) Fibrillar oligomers nucleate the oligomerization of monomeric A{beta}, but do not seed fibril formation. J Biol Chem.